Isophosphamide

Phase 2Small molecule

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Isophosphamide is one of 78 small molecule programs targeting Osteosarcoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteosarcomaNot yet recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

OsteosarcomaPhase 2

Not yet recruiting

Diffuse Large B-Cell LymphomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

103 competitors in Diffuse Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

38 2

Rituxan

Oncovin

32 4

Polivy

Roche

Phase 3

22 5

Gemzar

Johnson & Johnson

Phase 3

18 6

Oncovin

Eli Lilly

Phase 3

18 7

Adriamycin

Pfizer

Phase 3

18 8

Gazyva

Roche

Phase 3

17 9

Cytoxan

BBaxter Healthcare Corporation

Rayos

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Not yet recruiting

Osteosarcoma

NCT05590572

Clinical

Trials by Indication[1]

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00499343·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Isophosphamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Isophosphamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Isophosphamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital, School of Medicine, Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Isophosphamide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Osteosarcoma1 trial

Diffuse Large B-Cell Lymphoma1 trial

Stem Cell1 trial

References

Drug Info

Quick Facts

Related News